Orchard and Zealand Join Growing List Of Biotechs On The Ropes
Both Firms Forced To Restructure
Executive Summary
Orchard and Zealand are the latest European players to succumb to a financial pinch in the biotech sector, streamlining their pipelines and laying off staff to save on expenses.
You may also be interested in...
Is The Downturn A ‘Darwinian Moment’ For Biotech? The View From The Frontline
After the boom of 2020 and 2021, the biotech sector is experiencing one of the deepest and longest downturns but there are hopes that catalysts could soon revive confidence.
As Biotech M&A Activity Gingerly Rises, Regeneron Makes Moves On Checkmate
Regeneron hopes to bolster its immuno-oncology pipeline with the acquisition of Checkmate, which joins a spate of similar deals suggesting renewed interest in biotech investment despite an industry-wide slowdown.
Finance Watch: Q1 Biopharma IPOs Shrink To A Fraction Of 2021 Total
Public Company Edition: Only nine drug developers went public in the US, raising $807m in the first quarter, versus 32 IPOs raising $5.2bn in Q1 of last year. Also, MoonLake closed its SPAC merger, Sanofi priced €650m in sustainability-linked bonds in €1.5bn note sale, and Kaleido will cease operations.